Wanjarkhedkar Pankaj, Sarade Girish, Purandare Bharat, Kelkar Dhananjay
Department of Ayurveda & Integrative Medicine, Deenanath Mangeshkar Hospital and Research Centre, Pune, India.
Department of Ayurveda & Integrative Medicine, Deenanath Mangeshkar Hospital and Research Centre, Pune, India.
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100365. doi: 10.1016/j.jaim.2020.10.008. Epub 2020 Oct 19.
The ancient Indian system of medicine, Ayurveda has a treatment for symptom complexes of a variety of diseases. One such combination of Ayurvedic medications has potential for use in COVID 19 infection, and hence a prospective study was conducted with this formulation as an add-on, in COVID positive patients in a dedicated COVID hospital. The objective of the study was to evaluate the additional benefit of an Ayurvedic regime in COVID positive patients on the basis of rate of clinical improvement. The Ayurvedic formulation was administered as an add-on to Standard of Care (SoC) in patients with mild to moderate symptoms, in this prospective, open-label, comparative study. Control group received SoC only. Patients receiving and in tablet form in addition to the SoC showed a faster recovery from breathlessness with reduced ageusia. Patients on the treatment group could be discharged earlier than those from the control group. Addition of and to SoC appeared to accelerate recovery of patients hospitalized for COVID 19 infection, in terms of reduction of symptoms and duration of hospital stay.
古印度医学体系阿育吠陀对多种疾病的症状复合体有相应治疗方法。阿育吠陀药物的一种组合有用于治疗新冠病毒19感染的潜力,因此在一家专门的新冠医院,对新冠阳性患者开展了一项前瞻性研究,将这种配方作为附加治疗。该研究的目的是根据临床改善率评估阿育吠陀疗法对新冠阳性患者的额外益处。在这项前瞻性、开放标签的对照研究中,对于轻至中度症状的患者,阿育吠陀配方作为标准治疗(SoC)的附加治疗进行给药。对照组仅接受标准治疗。除标准治疗外,接受该阿育吠陀配方片剂治疗的患者呼吸急促恢复更快,味觉丧失减轻。治疗组患者比对照组患者能更早出院。在新冠病毒19感染住院患者中,在标准治疗基础上加用该阿育吠陀配方似乎能加速患者康复,在减轻症状和缩短住院时间方面均有体现。